MedTrace Logo

Does Human Skeletal Muscle Possess an Epigenetic Memory of Testosterone?

NCT05964920 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-03-06

No results posted yet for this study

Summary

This project's primary aim of this double-blinded, randomised, placebo-controlled trial is to investigate whether short-term testosterone administration +/- resistance exercise training induces a muscle memory response that can lead to longer-lasting benefits in aged human skeletal muscle.

The investigators will provide older men with the anabolic hormone, testosterone or placebo, with or without resistance training, followed by a period of testosterone abstinence and detraining, followed by a subsequent repeated period of resistance training (retraining). This will help determine if earlier encounters with short-term testosterone administration can be "remembered" and if adaptation to later retraining can be enhanced as a consequence of encountering testosterone earlier.

Conditions

  • Healthy Aging
  • Age-Related Sarcopenia
  • Testosterone Deficiency

Interventions

DRUG

Saline

Two placebo injections one at baseline and one week 3.

DRUG

Testosterone Undecanoate

Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3.

DRUG

Saline + Resistance exercise training

Two placebo injections one at baseline and one week 3 and10 weeks of supervised, structured, progressive resistance training.

DRUG

Testosterone Undecanoate + Resistance exercise training

Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3 and 10 weeks of supervised, structured, progressive resistance training.

Sponsors & Collaborators

  • Oslo University Hospital

    collaborator OTHER

  • Norwegian School of Sport Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2025-12-22
Completion
2026-02-06

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05964920 on ClinicalTrials.gov